Skin Cancer pp 89-108 | Cite as

Skin Adnexal Tumours: A Large Spectrum of Clinic-Pathological Lesions

  • Renato Franco
  • Maria Elena Errico
  • Federica Zito Marino
  • Anna Maria Anniciello
  • Gerardo Botti
  • Michele CaragliaEmail author
  • Anna Grimaldi
Part of the Current Clinical Pathology book series (CCPATH)


Skin adnexal neoplasms comprise a wide spectrum of more than 80 benign and malignant tumours, exhibiting morphological differentiation towards pilosebaceous unit, eccrine and apocrine glands. In addition more than one line of differentiation in this neoplasm could be observed. These tumours generally exhibit a benign behaviour, but malignant histotypes also exist. Clinical diagnosis of specific entity and of their potential malignancy is quite impossible. Thus, the diagnosis always requires surgical excision of skin lesion, and histological features at haematoxylin and eosin-stained sections are considered generally adequate for the correct classification of skin adnexal tumours. The use of histochemical and immunohistochemical stains could further aid in this purpose. Finally, they are usually encountered as single, sporadic tumours, but they may also occasionally be multiple and hereditary, heralding complex genetic syndromes that comprise visceral cancers.


Adenoid Cystic Carcinoma Apocrine Gland Sebaceous Carcinoma Adnexal Tumour Basaloid Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.




Adenomatous polyposis coli


Basal-cell carcinoma


Birt–Hogg–Dube’ syndrome


Cutaneous appendage tumors


Congenital hypertrophy of the retinal pigment epithelium


Cowden syndrome


Cutaneous sweat gland


Cutaneous sweat gland tumours


Familial adenomatous polyposis




Gardner syndrome


Haematoxylin and eosin


Multiple familial tricoepithelioma


Mammary-like glands


Muir–Torre syndrome


Nevus sebaceous of Jadassohn


Proliferating trichilemmal cyst


Phosphatase and TENsin


  1. 1.
    Rodriguez-Diaz E, Armio M. Mixed tumors with follicular differentiation: complex neoplasms of the primary epithelial germ. Int J Dermatol. 1994;34:782–5.CrossRefGoogle Scholar
  2. 2.
    Winship I, Dudding T. Lessons from the skin-cutaneous features of familial cancer. Lancet Oncol. 2008;9:462–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Kanitakis J. Adnexal tumors of the skin as markers of cancer-prone syndrome. J Eur Acad Dermatol Venereol. 2010;24:379–87.PubMedCrossRefGoogle Scholar
  4. 4.
    Klein W, Chan E, Seykora JT. Tumors of the epidermal appendages. In: Elder DE, editor. Lever’s histopathology of the skin. 9th ed. Philadelphia: Lippincott Williams & Wilikins; 2005. p. 867–926.Google Scholar
  5. 5.
    Weedon D. Tumors of cutaneous appendages. In: Weedon D, editor. Skin pathology. 2nd ed. Edinburgh: Churchill Livingstone; 2002. p. 859–916.Google Scholar
  6. 6.
    Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms—part 1: an approach to tumours of the pilosebaceous unit. J Clin Pathol. 2007;60:129–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Yoshida Y, Urabe K, Mashino T, et al. Basal cell carcinomas in association with basaloid follicular hamartoma. Dermatology. 2003;207:57–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Akasaka T, Kon S, Mihm Jr MC. Multiple basaloid cell hamartoma with alopecia and autoimmune disease (systemic lupus erythematosus). J Dermatol. 1996;23:821–4.PubMedGoogle Scholar
  9. 9.
    Morton S, Stevens A, Powell RJ. Basaloid follicular hamartoma, total body hair loss and SLE. Lupus. 1998;3:207–9.CrossRefGoogle Scholar
  10. 10.
    Jih DM, Shapiro M, James WD, et al. Familial basaloid follicular hamartoma: lesional characterization and review of the literature. Am J Dermatopathol. 2003;25:130–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Stern JB, Stout DA. Trichofolliculoma showing perineural invasion. Trichofolliculocarcinoma? Arch Dermatol. 1979;115:1003–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Plewig G. Sebaceous trichofolliculoma. J Cutan Pathol. 1980;7:394–403.PubMedCrossRefGoogle Scholar
  13. 13.
    Ramdial PK, Chrystal V, Madaree A. Folliculose baceous cystic hamartoma. Pathology. 1998;30:212–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Welsch MJ, Krunic A, Medenica MM. Birt-Hogg-Dube syndrome. Int J Dermatol. 2005;44:668–73.PubMedCrossRefGoogle Scholar
  15. 15.
    Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;6:980–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaceous: a study of 596 cases. J Am Acad Dermatol. 2000;42:263–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Xin H, Matt D, Qin JZ, et al. The sebaceous nevus: a nevus with deletions of the PTCH gene. Cancer Res. 1999;59:1834–6.PubMedGoogle Scholar
  18. 18.
    Harada H, Hashimoto K, Ko MS. The gene for multiple familial trichoepithelioma maps to chromosome 9p21. J Invest Dermatol. 1996;107:41–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang XJ, Liang YH, He PP, et al. Identification of the cylindromatosis tumor suppressor gene responsible for multiple familial trichoepithelioma. J Invest Dermatol. 2004;122:658–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Zheng G, Hu L, Huang W, et al. CYLD mutation causes multiple familial trichoepithelioma in three Chinese families. Hum Mutat. 2004;23:400.PubMedCrossRefGoogle Scholar
  21. 21.
    Kanitakis J, Bourchany D, Faure M, et al. Expression of the hair stem cell-specific keratin 15 in pilar tumours of skin. Eur J Dermatol. 1999;9:363–5.PubMedGoogle Scholar
  22. 22.
    Hunt SJ, Abell E. Malignant hair matrix tumor (“malignant trichoepithelioma”) arising in the setting of multiple hereditary trichoepithelioma. Am J Dermatopathol. 1991;13:275–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Matsuki T, Hayashi N, Mizushima J, et al. Two cases of desmoplastic trichoepithelioma. J Dermatol. 2004;31:824–7.PubMedGoogle Scholar
  24. 24.
    Jaqueti G, Requena L, Sanchez Yus E. Trichoblastoma is the most common neoplasm developed in nevus sebaceous of Jadassohn: a clinicopathologic study of a series of 155 cases. Am J Dermatopathol. 2000;22:108–18.PubMedCrossRefGoogle Scholar
  25. 25.
    Regauer S, Beham-Schmid C, Okuc M, et al. Trichoblastic carcinoma (“malignant trichoblastoma”) with lymphatic and hematogenous metastases. Mod Pathol. 2000;13:673–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Brownstein MH, Mehregan AH, Bikowski JB, et al. The dermatopathology of Cowden’s syndrome. Br J Dermatol. 1979;100:667–73.PubMedCrossRefGoogle Scholar
  27. 27.
    Hunt SJ, Kilzer B, Santa Cruz DJ. Desmoplastic trichilemmoma: histologic variant resembling invasive carcinoma. J Cutan Pathol. 1990;17:45–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Chan KO, Kim IJ, Baladas HG, et al. Multiple tumour presentation of trichilemmal carcinoma. Dermatol Surg. 2003;29:886–9.Google Scholar
  29. 29.
    Casas JG, Woscoff A. Giant pilar tumor of the scalp. Arch Dermatol. 1980;116:1395.PubMedCrossRefGoogle Scholar
  30. 30.
    Fernandez SH. Malignant proliferating trichilemmal tumour: a case report. Malays J Pathol. 1999;21:117–21.PubMedGoogle Scholar
  31. 31.
    Geh JL, Moss AL. Multiple pilomatrixomata and myotonic dystrophy: a familial association. Br J Plast Surg. 1999;52:143–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Noguchi H, Kayashima K, Nishiyama S, et al. Two cases of pilomatrixoma in Turner’s syndrome. Dermatology. 1999;199:338–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Xia J, Urabe K, Moroi Y, et al. beta-Catenin mutation and its nuclear localization are confirmed to be frequent causes of Wnt signaling pathway activation in pilomatricomas. J Dermatol Sci. 2006;41:67–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Bremnes RM, Kvamme JM, Stalsberg H, et al. Pilomatrix carcinoma with multiple metastases: report of a case and review of the literature. Eur J Cancer. 1999;35:433–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Misago N, Mihara I, Ansai S, et al. Sebaceoma and related neoplasms with sebaceous differentiation: a clinicopathologic study of 30 cases. Am J Dermato pathol. 2002;24:294–304.PubMedCrossRefGoogle Scholar
  36. 36.
    Bayer-Garner IB, Givens V, Smoller B. Immunohisto chemical staining for androgen receptors: a sensitive marker of sebaceous differentiation. Am J Dermato pathol. 1999;21:426–31.PubMedCrossRefGoogle Scholar
  37. 37.
    Sangueza OP. Hidrocistomas. Monogr Dermatol. 1993;6:146.Google Scholar
  38. 38.
    Boni R, Xin H, Hohl D, et al. Syringocystadenoma papilliferum: a study of potential tumor suppressor genes. Am J Dermatopathol. 2001;23:87–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Kazakow DV, Zelger B, Rütten A, et al. Morphologic diversity of malignant neoplasms arising in pre- existing spiradenoma, cylindroma, and spyradenocylindroma based on the study of 24 cases, sporadic or occuring in the setting of Brooke-Spiegler syndrome. Am J Surg Pathol. 2009;33:705–19.CrossRefGoogle Scholar
  40. 40.
    Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Mod Pathol. 2006;19:S93–S126.PubMedCrossRefGoogle Scholar
  41. 41.
    Urso C, Bondi R, Paglierani M, et al. Carcinomas of sweat glands: report of 60 cases. Arch Pathol Lab Med. 2001;125:498–505.PubMedGoogle Scholar
  42. 42.
    Akalin T, Sen S, Yuceturc A, et al. P53 protein expression in eccrine poroma and porocarcinoma. Am J Dermatopathol. 2001;23:402–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Waxtein L, Vega E, Cortes R, et al. Malignant nodular hidradenoma. Int J Dermatol. 1998;37:225–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Gerretsen AL, van der Putte SC, Deenstra W, et al. Cutaneous cylindroma with malignant transformation. Cancer. 1993;72:1618–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Granter SR, Seeger K, Calonje E, et al. Malignant eccrine spiradenoma (spiradenocarcinoma): a clinicopathologic study of 12 cases. Am J Dermatopathol. 2000;22:97–103.PubMedCrossRefGoogle Scholar
  46. 46.
    Satter EK, Graham BS. Chondroid syringoma. Cutis. 2003;71:49–52.PubMedGoogle Scholar
  47. 47.
    Yamamoto O, Yasuda H. An immunohistochemical study of the apocrine type of cutaneous mixed tumors with special reference to their follicular and sebaceous differentiation. J Cutan Pathol. 1999;26:232–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Nather A, Sutherland IH. Malignant transformation of a benign cutaneous mixed tumour. J Hand Surg [Br]. 1986;11:139–43.CrossRefGoogle Scholar
  49. 49.
    Wohlfahrt C, Ternesten A, Shalin P, et al. Cytogenetic and fluorescence in situ hybridization analysis of a microcystic adnexal carcinoma with del(6)(q23q25). Cancer Genet Cytogenet. 1997;98:106–10.PubMedCrossRefGoogle Scholar
  50. 50.
    Ban M, Sugie S, Kamiya H, et al. Microcystic adnexal carcinoma with lymph node metastasis. Dermatology. 2003;207:395–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Duke WH, Sherrod TT, Lupton GP. Aggressive digital papillary adenocarcinoma (aggressive digital papillary adenoma and adenocarcinoma revisited). Am J Surg Pathol. 2000;24:775–84.PubMedCrossRefGoogle Scholar
  52. 52.
    Chang SE, Ahn SJ, Choi JH, et al. Primary adenoid cystic carcinoma of skin with lung metastasis. J Am Acad Dermatol. 1999;40:640–2.PubMedCrossRefGoogle Scholar
  53. 53.
    Van der Kwast TH, Vuzevski VD, Ramaekers F, et al. Primary cutaneous adenoid cystic carcinoma: case report, immunohistochemistry, and review of the literature. Br J Dermatol. 1988;118:567–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Requena L, Kiryu H, Ackerman AB. Neoplasms with apocrine differentiation. Philadelphia: Lippincott Williams & Wilkins; 1998.Google Scholar
  55. 55.
    Quereshi HS, Salama ME, Chitale D, et al. Primary cutaneous mucinous carcinoma: presence of myoepithelial cells as a clue to the cutaneous origin. Am J Dermatopathol. 2004;26:353–8.CrossRefGoogle Scholar
  56. 56.
    Loane J, Kealy WF, Mulcahy G. Perianal hidradenoma papilliferum occurring in a male: a case report. Ir J Med Sci. 1998;16:726–7.Google Scholar
  57. 57.
    Miyamoto T, Hagari Y, Inoue S, et al. Axillary apocrine carcinoma with benign apocrine tumours: a case report involving a pathological and immunohistochemical study and review of the literature. J Clin Pathol. 2005;58(7):757–61.PubMedCrossRefGoogle Scholar
  58. 58.
    Van der Putte SC, Van Gorp LH. Adenocarcinoma of the mammary-like glands of the vulva: a concept unifying sweat gland carcinoma of the vulva, carcinoma of supernumerary mammary glands and extramammary Paget’s disease. J Cutan Pathol. 1994;21(2):157–63.PubMedCrossRefGoogle Scholar
  59. 59.
    Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms-part 2: an approach to tumours of cutaneous sweat glands. J Clin Pathol. 2007;60:145–59.PubMedCrossRefGoogle Scholar
  60. 60.
    Fistarol S, Anliker M, Itin P. Cowden disease or multiple hamartoma syndrome – cutaneous clues to internal malignancy. Eur J Dermatol. 2002;12:412–21.Google Scholar
  61. 61.
    Salem O, Steck W. Cowden’s Disease (multiple hamartoma syndrome). A case report and review of the English literature. J Am Acad Dermatol. 1983;8:686–96. 10.PubMedCrossRefGoogle Scholar
  62. 62.
    Starinck T, van der Veen J, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet. 1986;29:222–33.CrossRefGoogle Scholar
  63. 63.
    Ruhoy S, Thomas D, Nuovo G. Multiple inverted follicular keratoses as a presenting sign of Cowden’s syndrome: case report with human papillomavirus studies. J Am Acad Dermatol. 2004;51:411–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Pilarski R. Cowden’s syndrome: a critical review of the clinical literature. J Genet Couns. 2009;18:13–27.PubMedCrossRefGoogle Scholar
  65. 65.
    Waite K, Eng C. Protean PTEN: form and function. Am J Hum Genet. 2002;70:829–44.PubMedCrossRefGoogle Scholar
  66. 66.
    Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003; 22:183–98.Google Scholar
  67. 67.
    Squarize C, Castilho R, Gutkind J. Chemoprevention and treatment of experimental Cowden’s disease by mTOR inhibition with rapamycin. Cancer Res. 2008;68:7066–72.PubMedCrossRefGoogle Scholar
  68. 68.
    Ponti G, Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol. 2005;12:980–7.CrossRefGoogle Scholar
  69. 69.
    Akhtar S, Oza K, Khan S, Wright J. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature. J Am Acad Dermatol. 1999;41:681–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Cohen P, Kohn S, Kurzrock R. Association of sebaceous gland and internal malignancy: the Muir-Torre syndrome. Am J Med. 1991;90:606–13.PubMedGoogle Scholar
  71. 71.
    Kruse R, Rutten A, Lamberti C, et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair gene mutations similar to that in hereditary non-polyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet. 1998;63:63–70.PubMedCrossRefGoogle Scholar
  72. 72.
    South C, Hampel H, Comeras I, Westman J, Frankel W, de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst. 2008;100:277–81.PubMedCrossRefGoogle Scholar
  73. 73.
    Levi Z, Hazazi R, Kedar-Barnes I, et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. Am J Transplant. 2007;7:476–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Gaskin BJ, Fernando BS, Sullivan CA, et al. The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome. Br J Ophthalmol. 2011;95:1686–90.PubMedCrossRefGoogle Scholar
  75. 75.
    Groen E, Roos A, Muntinghe F, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol. 2008;15:2439–50.PubMedCrossRefGoogle Scholar
  76. 76.
    Lipton L, Tomlinson I. The genetics of FAP and FAP-like syndromes. Fam Cancer. 2006;5:221–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Goss K, Groden J. Biology of the adenomatous polyposis tumor suppressor gene. J Clin Oncol. 2000;18:1967–79.PubMedGoogle Scholar
  78. 78.
    Lynch PM. Chemoprevention with special reference to inherited colorectal cancer. Fam Cancer. 2008;7:59–64.PubMedCrossRefGoogle Scholar
  79. 79.
    Zbar B, Alvord W, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:393–400.PubMedGoogle Scholar
  80. 80.
    Adley B, Smith N, Nayar R, Yang X. Birt-Hogg-Dube’ syndrome. Clinicopathologic findings and genetic alterations. Arch Pathol Lab Med. 2006;130:1865–70.PubMedGoogle Scholar
  81. 81.
    Leter E, Koopmans A, Gille JJ, et al. Birt-Hogg-Dube syndrome: clinical and genetic studies of 20 families. J Invest Dermatol. 2008;128:45–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Toro J, Wei M, Glenn G, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube’ syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45:321–31.PubMedCrossRefGoogle Scholar
  83. 83.
    Warren M, Torres-Cabala C, Turner ML, et al. Expression of Birt- Hogg-Dube gene mRNA in normal and neoplastic human tissues. Mod Pathol. 2004;17:998–1011.PubMedCrossRefGoogle Scholar
  84. 84.
    Hartman T, Nicolas E, Klein-Szanto A, et al. The role of the Birt-Hogg-Dube’ protein in mTOR activation and renal tumorigenesis. Oncogene. 2009;28:1594–604.PubMedCrossRefGoogle Scholar
  85. 85.
    Baba M, Furihata M, Hong S, et al. Kidney-targeted Birt-Hogg-Dube’gene inactivation in a mouse model: Erk1⁄2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst. 2008;100:140–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Renato Franco
    • 1
  • Maria Elena Errico
    • 2
  • Federica Zito Marino
    • 1
  • Anna Maria Anniciello
    • 1
  • Gerardo Botti
    • 1
  • Michele Caraglia
    • 3
    Email author
  • Anna Grimaldi
    • 3
  1. 1.Pathology UnitNational Institute of Tumours Fondazione “G. Pascale”NaplesItaly
  2. 2.Pathology UnitPaediatric Hospital Santobono-PausiliponNaplesItaly
  3. 3.Department of Biochemistry and BiophysicsSecond University of NaplesNaplesItaly

Personalised recommendations